About this medicine
- Approved name
- Daruph and Anafezyn
- International non-proprietary name (INN) or common name
- dasatinib (anhydrous)
About this procedure
- Current status
- European Commission final decision
- Reference number
- EMEA/H/A-29(4)/1516
- Type
- Article 29(4) referrals
This type of referral is triggered when there is a disagreement between Member States regarding a marketing authorisation application being evaluated in a mutual-recognition or decentralised procedure, on the grounds of a potential serious risk to public health.
- Authorisation model
- Nationally authorised product(s)
- Decision making model
- CHMP-EC
Key dates and outcomes
- CHMP opinion date
- 19/05/2022
- EC decision date
- 18/07/2022